EUVIMEDEUVIMED entdecken
Crossref

Nuclear‐Targeted Boron‐Lapatinib Hybrid for Enhanced Boron Neutron Capture Therapy in Advanced Thyroid Carcinoma

Marcos Couto iD, Martina Buschittari, Marina Carpano, Susana Nievas, Belén Dávila iD, Antonella Pastini, Ignacio González iD, Marina Perona, María Sol Espain, Agustina Mariana Portu, Hugo Cerecetto iD, María Alejandra Dagrosa iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.202501074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Marcos Couto und 11 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Universidad de la República, Montevideo, Uruguay. Hauptthemen laut MEDLINE: Boron Neutron Capture Therapy, Thyroid Neoplasms, Antineoplastic Agents, Quinazolines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Dirección Nacional de Innovación, Ciencia y Tecnología (DICYTI), Uruguay, Scientific and Technical Research National Council (CONICET).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To enhance the effectiveness of boron neutron capture therapy (BNCT) for advanced thyroid carcinoma (ATC), we evaluated two previously synthesized boron‐enriched derivatives of Lapatinib incorporating high‐boron clusters. Lapatinib, a tyrosine kinase inhibitor (TKI), is clinically used in targeted therapy against tumor proliferation and progression. The compounds consisted of Lapatinib‐pharmacophore linked either to an ortho ‐carborane cluster ( Cmpd‐1 ) or to a metallacarborane cobalta‐bis‐dicarbollide ( COSAN ) anion ( Cmpd‐2 ). In vitro studies using the ATC 8505C anaplastic thyroid carcinoma cells showed significant cellular uptake of both compounds. Neutron autoradiography revealed that Cmpd‐2 is located predominantly within the nucleus, suggesting that nuclear targeting may contribute to its enhanced therapeutic potential. Subsequent BNCT irradiation experiments at the Argentine nuclear reactor RA‐3 demonstrated a marked reduction in cell survival, decreased Ki‐67 expression, and increased apoptosis for BNCT‐ Cmpd‐2 compared with BNCT using boronophenylalanine ( BPA , a standard positive control), neutron‐alone, and control groups. In vivo studies in ATC xenografted nude mice confirmed the absence of systemic toxicity and a significant inhibition of tumor growth following Cmpd‐2 treatment ( p < 0.01). Boron biodistribution analyses revealed favorable tumor‐to‐blood ratios (>3) when Cmpd‐2 was combined with BPA . Overall, these results support Cmpd‐2 as a promising bimodal agent for targeted and neutron‐based therapy of advanced thyroid cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron Neutron Capture TherapyThyroid NeoplasmsAntineoplastic AgentsQuinazolinesBoronProtein Kinase InhibitorsHumansAnimalsMiceCell Line, TumorMice, NudeCell ProliferationApoptosisCell SurvivalCarboranesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

advanced thyroid carcinomaboron neutron capture therapycarboranematallacarboranetyrosine kinase inhibitor

Substanzen

Antineoplastic AgentsQuinazolinesCarboranesBoronProtein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Universidad de la República, Montevideo, Uruguay.
  • Instituto de Investigación Una Salud, Universidad de la República, Montevideo, Uruguay.
  • Comisión Nacional de Energía Atómica (CNEA), Ciudad Autónoma de Buenos Aires, Argentina.
  • Graduate Program in Chemistry, Universidad de la República, Montevideo, Uruguay.
  • Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina.

ORCID-Profile: Marcos Couto, Belén Dávila, Ignacio González, Hugo Cerecetto, María Alejandra Dagrosa

Förderung

  • Dirección Nacional de Innovación, Ciencia y Tecnología (DICYTI), Uruguay
  • Scientific and Technical Research National Council (CONICET)

Zitieren

APA

Couto, M., Buschittari, M., Carpano, M., Nievas, S., Dávila, B., Pastini, A., González, I., Perona, M., Espain, M. S., Portu, A. M., Cerecetto, H., & Dagrosa, M. A. (2026). Nuclear‐Targeted Boron‐Lapatinib Hybrid for Enhanced Boron Neutron Capture Therapy in Advanced Thyroid Carcinoma. ChemMedChem. https://doi.org/10.1002/cmdc.202501074

Vancouver

Couto M, Buschittari M, Carpano M, Nievas S, Dávila B, Pastini A, et al. Nuclear‐Targeted Boron‐Lapatinib Hybrid for Enhanced Boron Neutron Capture Therapy in Advanced Thyroid Carcinoma. ChemMedChem. 2026. doi:10.1002/cmdc.202501074

BibTeX
@article{Couto2026,
  author = {Couto, Marcos and Buschittari, Martina and Carpano, Marina and Nievas, Susana and Dávila, Belén and Pastini, Antonella and González, Ignacio and Perona, Marina and Espain, María Sol and Portu, Agustina Mariana and Cerecetto, Hugo and Dagrosa, María Alejandra},
  title = {Nuclear‐Targeted Boron‐Lapatinib Hybrid for Enhanced Boron Neutron Capture Therapy in Advanced Thyroid Carcinoma},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.202501074}
}
Kostenlos starten →